A primary finding of this study is that CXCR2-driven cancer progression involves upregulation of its own ligands such as CXCL1 and CXCL2 by potentiating NF-κB activation via EGFR-transactivated Akt signaling followed by accelerated ovarian cancer cell proliferation, migration and invasion. This evidence concerns the gene CXCR2 and ovarian carcinoma.